Bahl & Gaynor’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-9,129
| Closed | -$430K | – | 340 |
|
|
2020
Q3 | $430K | Hold |
9,129
| – | – | ﹤0.01% | 288 |
|
|
2020
Q2 | $465K | Buy |
9,129
+547
| +6% | +$28.1K | ﹤0.01% | 287 |
|
|
2020
Q1 | $406K | Sell |
8,582
-802
| -9% | -$42.8K | ﹤0.01% | 293 |
|
|
2019
Q4 | $551K | Buy |
9,384
+255
| +3% | +$14.2K | ﹤0.01% | 303 |
|
|
2019
Q3 | $487K | Hold |
9,129
| – | – | ﹤0.01% | 306 |
|
|
2019
Q2 | $457K | Sell |
9,129
-24
| -0.3% | -$1.2K | ﹤0.01% | 310 |
|
|
2019
Q1 | $478K | Sell |
9,153
-991
| -10% | -$49.5K | ﹤0.01% | 300 |
|
|
2018
Q4 | $485K | Hold |
10,144
| – | – | 0.01% | 293 |
|
|
2018
Q3 | $509K | Hold |
10,144
| – | – | 0.01% | 304 |
|
|
2018
Q2 | $511K | Sell |
10,144
-2,223
| -18% | -$112K | 0.01% | 306 |
|
|
2018
Q1 | $604K | Buy |
12,367
+102
| +0.8% | +$4.75K | 0.01% | 313 |
|
|
2017
Q4 | $544K | Hold |
12,265
| – | – | 0.01% | 327 |
|
|
2017
Q3 | $622K | Hold |
12,265
| – | – | 0.01% | 307 |
|
|
2017
Q2 | $661K | Sell |
12,265
-1,600
| -12% | -$85.3K | 0.01% | 307 |
|
|
2017
Q1 | $731K | Sell |
13,865
-120
| -0.9% | -$6.09K | 0.01% | 285 |
|
|
2016
Q4 | $673K | Buy |
13,985
+120
| +0.9% | +$5.93K | 0.01% | 288 |
|
|
2016
Q3 | $747K | Sell |
13,865
-612
| -4% | -$33.6K | 0.01% | 270 |
|
|
2016
Q2 | $784K | Sell |
14,477
-1,658
| -10% | -$87.3K | 0.01% | 259 |
|
|
2016
Q1 | $818K | Sell |
16,135
-3,697
| -19% | -$184K | 0.01% | 251 |
|
|
2015
Q4 | $1M | Sell |
19,832
-6,778
| -25% | -$345K | 0.01% | 233 |
|
|
2015
Q3 | $1.28M | Sell |
26,610
-1,773
| -6% | -$92.3K | 0.02% | 200 |
|
|
2015
Q2 | $1.48M | Sell |
28,383
-2,616
| -8% | -$147K | 0.02% | 196 |
|
|
2015
Q1 | $1.79M | Sell |
30,999
-4,522
| -13% | -$259K | 0.02% | 186 |
|
|
2014
Q4 | $1.9M | Sell |
35,521
-12,566
| -26% | -$703K | 0.03% | 181 |
|
|
2014
Q3 | $2.76M | Sell |
48,087
-894,234
| -95% | -$54.8M | 0.04% | 150 |
|
|
2014
Q2 | $63M | Buy |
942,321
+218,827
| +30% | +$14.8M | 0.96% | 38 |
|
|
2014
Q1 | $48.3M | Buy |
723,494
+18,052
| +3% | +$1.22M | 0.77% | 46 |
|
|
2013
Q4 | $47.1M | Buy |
705,442
+21,061
| +3% | +$1.37M | 0.77% | 46 |
|
|
2013
Q3 | $42.9M | Buy |
684,381
+32,551
| +5% | +$2.1M | 0.77% | 52 |
|
|
2013
Q2 | $40.7M | Buy |
+651,830
| New | +$41.4M | 0.77% | 47 |
|
Other funds holding GSK
BCIM